Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Asunto principal
Intervalo de año de publicación
1.
J Clin Hypertens (Greenwich) ; 22(12): 2285-2295, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33045133

RESUMEN

Hypertension is the leading risk factor for cardiovascular disease (CVD) worldwide. Despite the availability of effective antihypertensive medications, the control of hypertension at a global level is dismal, and consequently, the CVD burden continues to increase. In response, countries in Latin America and the Caribbean are implementing the HEARTS in the Americas, a community-based program that focuses on increasing hypertension control and CVD secondary prevention through risk factor mitigation. One key pillar is the implementation of a standardized hypertension treatment protocol supported by a small, high-quality formulary. This manuscript describes the methodology used by the HEARTS in the Americas program to implement a population-based standardized hypertension treatment protocol. It is rooted in a seamless transition from existing treatment practices to best practice using pharmacologic protocols built around a core set of ideal antihypertensive medications. In alignment with recent major hypertension guidelines, the HEARTS in the Americas protocols call for the rapid control of blood pressure, through the use of two antihypertensive medications, preferably in the form of a single pill, fixed-dose combination, in the initial treatment of hypertension. To date, the HEARTS in the Americas program has seen the improvement in antihypertensive medication formularies and the establishment of pharmacologic treatment protocols tailored to individual participating countries. This has translated to significant increases in hypertension control rates post-program implementation in these jurisdictions. Thus, the HEARTS in the Americas program could serve as a model, for not only the Americas Region but globally, and ultimately decrease the burden of CVD.


Asunto(s)
Hipertensión , Antihipertensivos/uso terapéutico , Región del Caribe , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/epidemiología , Hipertensión/prevención & control , América Latina , Atención Primaria de Salud
2.
J Rehabil Assist Technol Eng ; 6: 2055668319862137, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-35186318

RESUMEN

The increasing availability of wearable devices (wearables), "smart" home, and other next-generation wirelessly connected devices for work, home, and leisure presents opportunities and challenges for users with disabilities. As augmentative tools for engagement, control, and information, these technologies should not only be usable, but also be accessible and inclusive for people with disabilities. In order to better capture the dimensions of inclusivity of wearable devices, the authors have conducted a review of pertinent literature with respect to a range of representative applications and examples of currently available technologies. Drawing on the findings of the review, the aim of this article is to explore the potential impact of inclusive design principles on future device development for users with disabilities. These observations can help designers incorporate inclusive perspectives into the development process. Such an approach, where people with disabilities constitute an integral part of the development process, will yield products and services that can facilitate increased accessibility, independence, and community participation.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...